Small Cap Losers: RDUS, VRA, WEAV
4:55 pm Wednesday, December 08th, 2021
Radius Health Inc (NASDAQ:RDUS) announced results from the wearABLe trial evaluating abaloparatide transdermal system (abalo-TDS) vs abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis. The study did not meet its primary endopint, as it did not demonstrate the non-inferiority of abalo-TDS to TYMLOS. Co also highlighted the presentation of results from the EMERALD trial of elacestrant for the treatment of ER+/HER2- advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium. Falls to multi-year lows.
Vera Bradley, Inc. (NASDAQ:VRA) reported downside Q3 results while issuing a downside outlook for Q4. Vera Bradley brand comp sales rose nearly +8% over the prior year; e-commerce revs for Pura Vida continued to be “suppressed” by Apple’s iOS 14.5 update, which lessened the effectiveness of Pura Vida’s primary marketing vehicles to drive sales. Supply chain challenges pressured margins in the quarter; co has begun to take strategic retail price increases to mitigate those pressures.
Weave Communications Inc (NYSE:WEAV) missed consensus for Q3 EPS on upside revs. Co added 1,326 net new customer locations in the quarter and had 22,553 customer locations as of September 30. Issued in-line Q4 revs guidance. The November IPO reaches new lows.
